Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
Surufatinib showed superior efficacy in extrapancreatic neuroendocrine tumors. Eligible patients were adults with progressive, advanced, well-differen...
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
CH5126766 is a novel MEK-pan-RAF inhibitor. The initial development of this drug was limited by toxicity. We evaluated three intermittent oral schedul...
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
This report provides updated 4-year efficacy, initial overall survival, and late-emergent safety results. Patients aged 15 years or older with resecte...
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
Trastuzumab was administered intravenously every 3 weeks for 18 doses or weekly for 9 weeks. 5-year distant metastasis-free survival rates were 98% fo...
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial
POETIC was an open-label, multicentre, parallel-group, randomized, phase 3 trial done in 130 UK hospitals. Postmenopausal women aged at least 50 years...
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Activating mutations of EZH2, an epigenetic regulator, are present in 20% of follicular lymphoma patients. Tazemetostat monotherapy showed clinically...
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Epithelioid sarcoma is a rare and aggressive soft-tissue sarcomo subtype. Over 90% of tumours have lost INI1 expression, leading to oncogenic dependen...
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
This was an open-label, multicentre, single-arm phase 2 trial done at 18 hospitals in Spain. At 24 months, progression-free survival was 77% in patien...
Recent Posts
-
-
What Causes Sciatica | Dr. Kalyan Bommakanti
11 May 2022 -
